China Powers Into Precision Medicine
This article was originally published in The Gray Sheet
Executive Summary
Metastatic tumors, diabetes, cardiovascular and rare diseases are among the areas being targeted in China’s new precision medicine initiative in a bet that could be worth $10 billion by 2030.